1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62F1E549DEA3B0656002585C2003FCFFC
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/maximizing-impact-analytics-and-insights-teams-across-biopharma-organization?opendocument
18
19opendocument
2018.234.255.5
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Market Research, Analytics and Forecasting » Analytics

Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization

ID: PSM-366


Features:

35 Info Graphics

44 Data Graphics

1230+ Metrics

33 Narratives


Pages: 91


Published: 2020


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Forward-looking Analytics & Insights (A&I) teams are using ever-increasing access to data, advanced methodologies, and a confident approach to strategy to drive innovation across a growing spectrum of internal biopharma customer groups.

Best Practices, LLC conducted this benchmark research to help biopharma A&I and Market Research groups maximize their impact and enhance their standing not only with brand teams and franchises, but also with medical affairs, HEOR, market access, corporate and other key stakeholders.

This report examines how leading industry competitors leverage their analytics and talent to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, promote innovation and scale successes.

The report also probes the use of Internal Branding programs for A&I teams, the role they play in supporting Innovation Centers of Excellence, and the new opportunities and challenges that have emerged for A&I groups as a result of COVID-19.

Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Research; Consulting; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alcon; Alkermes; Amgen; Arena Pharmaceuticals; AstraZeneca; Atara Biotherapeutics; Bayer; Bio-Rad Laboratories; Inc.; Biotest AG; Biotronik; Boehringer Ingelheim; B.Braun; Dermira; Edwards Lifesciences; GlaxoSmithKline ; Grünenthal; Janssen; Klosterfrau Healthcare Group; LEO Pharma; Lonza Inc.; MEDiSTRAVA; Merck; Merck Sharp & Dohme; Mitsubishi Tanabe Pharma; Momenta; Novartis; Pfizer; Qiagen; REGENXBIO Inc.; Sanofi; Santen; Scilex Pharmaceuticals; Seqirus; Servier; Sunovion; Takeda Pharmaceuticals; UCB Pharma; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 44 Analytics and Insights professionals from 38 leading biopharma organizations in this research through a benchmark survey. Data in this report are segmented by mid vs. large pharma companies. Deep-dive interviews were conducted with selected benchmark participants to provide further insights. Over 85% of research participants serve at the director level or above.

Key topics covered in this report include:

  • Core A&I responsibilities and clients supported
  • Valuable strategic practices, skills and expertise areas
  • High-value analytics, methodologies, platforms and outsourcing approaches
  • Streamlining market research via analytics
  • Internal branding programs
  • Innovation centers of excellence: Usage, staffing, services and alignment
  • Top A&I obstacles, mistakes and lessons
  • Innovative pilots, design thinking and patient engagement
  • A&I support during COVID-19 and beyond


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Clients supported: A&I teams spend just 38% of time supporting brands, spending the balance on franchises, commercial dev, HEOR, medical, C-suite & others.

  • Analytics: Greater access to data is driving increased use of advanced analytics, especially for commercial customers (forecasting, mining, AI, conjoint, sentiment & regression). A&I teams often insource higher-value projects. Some competitors have replaced traditional market research studies (forecasting, segmentation) with analytics.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive summaryPg. 3-14
II.
Research overview, methodology & participating companiesPg. 4-7
III.
Key study findingsPg. 8-14
IV.
Section I: Analytics & Insights group: Core responsibilities and internal partners supportedPg. 15-20
V.
Section II: How a strong Analytics & Insights function delivers valuePg. 21-35
VI.
Section III: Optimizing advanced analytics capabilitiesPg. 36-62
VII.
Section IV: Assessing the impact of internal department branding programsPg. 63-69
VIII.
Section V: Innovation Centers of ExcellencePg. 70-77
IX.
Section VI: Design thinking, patient engagement & other innovative projectsPg. 78-83
X.
Section VII: Analytics & Insights team support during COVID-19 and beyondPg. 84-86
XI.
APPENDIX: Snapshot of benchmark participantsPg. 87-90
XII.
About Best Practices, LLCPg. 91

    List of Charts & Exhibits

    I. Analytics & Insights Group: Core Responsibilities and Internal Partners Supported

    • Percentage of time spent by Analytics & Insights groups in support of various internal teams – Total benchmark class
    • Percentage of time spent by Analytics & Insights groups in support of various internal teams – Large pharma and mid-pharma
    • Voices from the field: Building holistic view for improving business results
    • Role played by Analytics & Insights groups in fulfilling the listed organizational capabilities – Total benchmark class
    • Role played by Analytics & Insights groups in fulfilling the listed organizational capabilities – Large pharma and mid-pharma

    II. How a Strong Analytics & Insights Function Delivers Value

    • Effective practices used by Analytics & Insights groups to provide greater value to stakeholders – Total benchmark class
    • Voices from the field: Making consensual and collaborative plans and recommendations to clients
    • Effective practices used by Analytics & Insights groups to provide greater value to stakeholders – Large pharma and mid-pharma
    • Preferred professional experiences and soft skills for Analytics & Insights professionals to have in order to deliver the highest value to internal partners – Total benchmark class
    • Interview narratives around staffing an analytics organization
    • Preferred professional experiences and soft skills for Analytics & Insights professionals to have in order to deliver the highest value to internal partners – Large pharma and mid-pharma
    • Most critical knowledge areas and technical skills for Analytics & Insights team members to have in order to provide maximum value as a strategy partner to internal partners – Total benchmark class
    • Most critical knowledge areas and technical skills for Analytics & Insights team members to have in order to provide maximum value as a strategy partner to internal partners – Large pharma and mid-pharma
    • Greatest challenges to the future success of the Analytics & Insights function – Total benchmark class
    • Interview narratives around what can drive the approach to analytics capabilities
    • Interview narrative around analytics and different therapeutic areas
    • Greatest obstacles to the future success of the Analytics & Insights function – Large pharma and mid-pharma
    • Common mistake areas for the Analytics & Insights function
    • Innovative ways to foster ongoing innovation in providing greater value to stakeholders

    III. Optimizing Advanced Analytics Capabilities

    • Analytic methodologies used by Analytics & Insights groups for different operational purposes – Total benchmark class
    • Analytic methodologies used by Analytics & Insights groups for different operational purposes – Strategic A&I teams vs. total benchmark class
    • Interview narrative around determining “Next Best Action” in promotional mix
    • Analytic methodologies used by Analytics & Insights groups for different operational purposes – Large pharma and mid-pharma
    • Interview narrative around predictive analytics in R&D
    • Valuable analytics projects for informing brand, HEOR and other key internal partner teams and driving measurable results in the market – Total benchmark class
    • Valuable analytics projects for informing brand, HEOR and other key internal partner teams and driving measurable results in the market – Strategic A&I teams
    • Interview narratives around the outputs from new analytics platforms
    • Interview narratives around data mining and usage with digitization
    • Valuable analytics projects for informing brand, HEOR and other key internal partner teams and driving measurable results in the market – Large pharma and mid-pharma
    • Interview narrative around characterizing the activities that are enabling to connect the dots, in terms of analytic operations and methodologies performed
    • Insource vs. outsource approach for analytics projects – Total benchmark class
    • Insource vs. outsource approach for analytics projects – Strategic A&I teams
    • Interview narrative around benefits of insourcing analytics
    • Insource vs. outsource approach for analytics projects – Large pharma and mid-pharma
    • Insource vs. outsource approach for specific methodologies and processes – Total benchmark class
    • Insource vs. outsource approach for specific methodologies and processes – Large pharma and mid-pharma
    • Use of analytics to replace listed market research study types – Total benchmark class
    • Interview narratives around opportunities for more boutique research methodologies
    • Interview narratives around approaches that tend to stifle innovation
    • Use of analytics to replace listed market research study types – Large pharma and mid-pharma
    • Platforms used by organizations for analytics
    • Platforms used by organizations for reporting
    • Benchmark peer assessments (pros and cons) of leading analytics platforms
    • Preferred analytics platforms

    IV: Assessing the Impact of Internal Department Branding Programs

    • Internal branding campaign to change or influence the perception of the Analytics & Insights function and the types of work it conducts
    • Important objectives for Analytics & Insights internal branding program – Total benchmark class
    • Structural challenges, different data sources, and interview narrative around Analytics & Insights from medical perspective
    • Important objectives for Analytics & Insights internal branding program – Large pharma and mid-pharma
    • Vendor support and budget for internal branding efforts
    • Measurement and overall impact of formal branding efforts

    V. Innovation Centers of Excellence

    • Presence of an innovation center of excellence (CoE) to leverage expertise and drive new improvements – Total benchmark class
    • Interview narrative around innovation centers of excellence
    • Presence of an innovation CoE to leverage expertise and drive new improvements – Large pharma and mid-pharma
    • Relationship between innovation CoE (or similar department) and Analytics & Insights groups
    • Number of FTEs working in innovation CoE or similar departments
    • Effective services delivered by innovation CoE (or similar groups) in supporting the overall organization
    • Critical professional experiences for staff working in an innovation CoE or similar department

    VI. Design Thinking, Patient Engagement & Other Innovative Projects

    • Employment of a formal design thinking methodology to achieve better performance over time
    • Engaging directly with patients to better understand and meet their lifestyle needs relative to the disease state treated by the company’s medicines
    • Examples of patient engagement programs of benchmark partners
    • Disease areas in which benchmark organizations have made a positive impact using patient engagement programs to better meet patient needs – Primary care, specialty, and rare diseases
    • Disease areas in which benchmark organizations have made a positive impact using patient engagement programs to better meet patient needs – Drug routes and drug types

    VII. Analytics & Insights Team Support During COVID-19 and Beyond

    • Support provided by Analytics & Insights groups to internal stakeholders during the COVID-19 pandemic
    • Key new opportunities and challenges that have emerged for Analytics & Insights groups as a result of COVID-19